Header Logo

Connection

PEDRO PIEDRA to Middle Aged

Back to Details
This is a "connection" page, showing publications PEDRO PIEDRA has written about Middle Aged.
PEDRO PIEDRA
Connection Strength
0.388
Middle Aged
  1. Longitudinal host transcriptional responses to SARS-CoV-2 infection in adults with extremely high viral load. PLoS One. 2025; 20(1):e0317033.
    View in: PubMed
    Score: 0.059
  2. Viral Load of Severe Acute Respiratory Syndrome Coronavirus 2 in Adults During the First and Second Wave of Coronavirus Disease 2019 Pandemic in Houston, Texas: The Potential of the Superspreader. J Infect Dis. 2021 05 20; 223(9):1528-1537.
    View in: PubMed
    Score: 0.046
  3. Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients. J Infect Dis. 2018 03 28; 217(8):1247-1256.
    View in: PubMed
    Score: 0.037
  4. Infection with novel respiratory syncytial virus genotype Ontario (ON1) in adult hematopoietic cell transplant recipients, Texas, 2011-2013. J Infect Dis. 2015 Feb 15; 211(4):582-9.
    View in: PubMed
    Score: 0.029
  5. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013 Jan 07; 31(3):524-32.
    View in: PubMed
    Score: 0.025
  6. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis. 2012 Apr; 54(7):905-12.
    View in: PubMed
    Score: 0.024
  7. Societal and economic consequences of influenza. Manag Care. 2008 Oct; 17(10 Suppl 10):8-14.
    View in: PubMed
    Score: 0.019
  8. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
    View in: PubMed
    Score: 0.018
  9. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18; 23(13):1540-8.
    View in: PubMed
    Score: 0.015
  10. Respiratory Viral Infections and Infection Prevention Practices Among Women With Acute Respiratory Illness During Delivery Hospitalizations During the 2019-2020 Influenza Season. J Infect Dis. 2022 01 05; 225(1):50-54.
    View in: PubMed
    Score: 0.012
  11. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020 11 25; 38(50):7892-7896.
    View in: PubMed
    Score: 0.011
  12. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 12 10; 383(24):2320-2332.
    View in: PubMed
    Score: 0.011
  13. Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017 09 15; 216(6):678-687.
    View in: PubMed
    Score: 0.009
  14. Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017 07 15; 216(2):153-161.
    View in: PubMed
    Score: 0.009
  15. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
    View in: PubMed
    Score: 0.008
  16. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
    View in: PubMed
    Score: 0.008
  17. Influenza virus pneumonia: pathogenesis, treatment, and prevention. Semin Respir Infect. 1995 Dec; 10(4):216-23.
    View in: PubMed
    Score: 0.008
  18. Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes. J Med Virol. 2016 Apr; 88(4):719-23.
    View in: PubMed
    Score: 0.008
  19. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
    View in: PubMed
    Score: 0.007
  20. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.007
  21. Community-acquired pneumonia in Chile: the clinical relevance in the detection of viruses and atypical bacteria. Thorax. 2013 Nov; 68(11):1000-6.
    View in: PubMed
    Score: 0.007
  22. Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness. J Clin Microbiol. 2012 Feb; 50(2):506-8.
    View in: PubMed
    Score: 0.006
  23. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005 May; 50(4):322-30.
    View in: PubMed
    Score: 0.004
  24. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000 Jan 26; 283(4):499-505.
    View in: PubMed
    Score: 0.003
  25. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995 Sep; 16(3):393-9.
    View in: PubMed
    Score: 0.002
  26. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol. 1991 Feb 01; 133(3):296-304.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.